Literature DB >> 16219950

Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.

C M Ng1, H K L Yuen, K L Choi, M K Chan, K T Yuen, Y W Ng, S C Tiu.   

Abstract

OBJECTIVE: To assess the efficacy and safety of combined orbital irradiation and systemic steroids in the management of moderate-to-severe Graves' ophthalmopathy.
DESIGN: Single-blind randomised prospective study.
SETTING: Regional hospital, Hong Kong. PATIENTS: Sixteen patients with active moderate-to-severe Graves' ophthalmopathy who were randomly assigned to steroid therapy (ST group) or combination therapy of orbital irradiation and systemic steroids (SRT group) between June 2000 and June 2003. MAIN OUTCOME MEASURES: NOSPECS scoring system, total eye score, subjective eye score, and extra-ocular muscle thickness as determined by either computed tomographic or magnetic resonance imaging scans.
RESULTS: The study was completed by 15 of 16 patients. Both groups experienced improvement in total eye score, soft tissue swelling, ocular motility, visual acuity, and subjective eye score at 52-week follow-up. Total eye score improved earlier in the SRT group, achieving statistical significance (P<0.05) at as early as 4 weeks of follow-up. Improvement in ocular parameters was greater and led to a significantly greater reduction in total eye score than in the ST group at weeks 16, 24, and 52. Maximum extra-ocular muscle thickness was significantly reduced in the SRT group only. No change was observed in proptosis in either group. No serious adverse effect was observed with the addition of orbital irradiation to steroid therapy.
CONCLUSION: A combination of orbital irradiation and systemic steroids is well tolerated and more effective than steroids alone in the treatment of active moderate-to-severe Graves' ophthalmopathy. It achieves greater and more rapid improvement in soft tissue swelling, ocular motility, and visual acuity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219950

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  20 in total

1.  Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.

Authors:  Ji Won Kim; Sun Hyup Han; Byeong Jae Son; Tyler Hyungtaek Rim; Ki Chang Keum; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-15       Impact factor: 3.117

2.  Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.

Authors:  Zichang Ma; Hiroshi Ozaki; Yojiro Ishikawa; Keiichi Jingu
Journal:  Jpn J Radiol       Date:  2019-06-14       Impact factor: 2.374

Review 3.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

4.  Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.

Authors:  Luigi Bartalena; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2020-09-21

5.  Feasibility of tomotherapy for Graves' ophthalmopathy: Dosimetry comparison with conventional radiotherapy.

Authors:  Nam P Nguyen; Shane P Krafft; Paul Vos; Vincent Vinh-Hung; Misty Ceizyk; Siyoung Jang; Anand Desai; Dave Abraham; Lars Ewell; Christopher Watchman; Russ Hamilton; Beng-Hoey Jo; Ulf Karlsson; Lexie Smith-Raymond
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

Review 6.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 7.  Dose of intravenous steroids and therapy outcome in Graves' orbitopathy.

Authors:  S Zang; K A Ponto; S Pitz; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

Review 8.  Rituximab for thyroid-associated ophthalmopathy.

Authors:  Swan Kang; Shirin Hamed Azzam; Neda Minakaran; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

9.  A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.

Authors:  Kristian T M Johnson; Andrea Wittig; Christian Loesch; Joachim Esser; Werner Sauerwein; Anja K Eckstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-29       Impact factor: 3.117

10.  Outcome of thyroid associated ophthalmopathy treated by radiation therapy.

Authors:  Mirna Abboud; Asma Arabi; Ibrahim Salti; Fady Geara
Journal:  Radiat Oncol       Date:  2011-05-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.